Accelerated PIVOT-006 Timeline and Expanded NMIBC Opportunity Drive CG Oncology Target Hike to $108 and Reinforce Buy Rating
I'm PortAI, I can summarize articles.
Analyst Sam Slutsky of LifeSci Capital has maintained a Buy rating on CG Oncology, Inc., raising the price target to $108 due to the accelerated PIVOT-006 Phase 3 trial for cretostimogene in treating intermediate-risk non-muscle invasive bladder cancer. The trial is progressing faster than expected, with topline data anticipated in early 2026. Slutsky's valuation now includes the intermediate-risk NMIBC opportunity, reflecting a higher risk-adjusted value. JonesTrading also reiterated a Buy rating with a $85 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments